

09/810490

Search result

Refine Search

Your wildcard search against 10000 terms has yielded the results below.

Your result set for the last L# is incomplete.

The probable cause is use of unlimited truncation. Revise your search strategy to use limited truncation.

Search Results -

Terms	Documents
viral near5 (gene or genes) near5 (function\$ or activ\$) near10 complement\$ near5 (cell or cells) near10 (nonfunctional or inactiv\$)	5

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L22

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Sunday, June 06, 2004 [Printable Copy](#) [Create Case](#)

Set Name	Query	Hit Count	Set Name result set
side by side			
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
<u>L22</u>	viral near5 (gene or genes) near5 (function\$ or activ\$) near10 complement\$ near5 (cell or cells) near10 (nonfunctional or inactiv\$)	5	<u>L22</u>
<u>L21</u>	adenovir\$ near5 vector\$ and (inducer\$ or repressor\$) near5 viral near5 (gene or genes)	27	<u>L21</u>
<u>L20</u>	5856152 [pn]	2	<u>L20</u>
<u>L19</u>	E1 near5 delet\$ and complement\$ near5 293 near (cell or cells) and titer\$ near10 (plaque\$ or pfu\$)	69	<u>L19</u>
<u>L18</u>	L11 and titer\$ near10 (plague\$ or pfu\$)	36	<u>L18</u>
<u>L17</u>	(inducer\$ or repressor\$) near5 complement\$ near5 (cell or cells)	13	<u>L17</u>
<u>L16</u>	(inducer\$ or repressor\$) near5 complementat\$ near5 (cell or cells)	3	<u>L16</u>

<u>L15</u>	L13 and (plaque\$ or pfu)	1	<u>L15</u>
<u>L14</u>	L13 and (palque or pfu)	1	<u>L14</u>
<u>L13</u>	5585362 [pn]	2	<u>L13</u>
<u>L12</u>	L11 and 108	45	<u>L12</u>
<u>L11</u>	L10 and (plaque\$ or pfu)	152	<u>L11</u>
<u>L10</u>	E1 near5 delet\$ and complement\$ near5 293 near (cell or cells)	172	<u>L10</u>
<u>L9</u>	L2 and plaque	1	<u>L9</u>
<u>L8</u>	L2 and inducer\$	2	<u>L8</u>
<u>L7</u>	("E1" or "E1a" or "E1b") near10 (trans near activat\$ or transactivat\$) near10 ("E4" or E2 or E4\$ or E2\$)	84	<u>L7</u>
<u>L6</u>	("E1" or "E1a" or "E1b") near5 trans near5 "E4"	22	<u>L6</u>
<u>L5</u>	("E1" or "E1a" or "E1b") near5 "E4"	4748	<u>L5</u>
<u>L4</u>	l2 and expression near unit\$	2	<u>L4</u>
<u>L3</u>	l2 and expression nera unit\$	6277903	<u>L3</u>
<u>L2</u>	6204060 [pn]	2	<u>L2</u>
<u>L1</u>	6204060 p[pn]	22	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 69 of 69 returned.**

-
- ☐ 1. [20040086486](#). 11 Jul 03. 06 May 04. Method of enhancing delivery of a therapeutic nucleic acid. Barsoum, James G., et al. 424/93.2; 424/450 435/456 514/34 A61K048/00 A61K009/127 C12N015/86 A61K031/704.
-
- ☐ 2. [20040048243](#). 02 Sep 03. 11 Mar 04. Methods and compositions for in vitro targeting. Arap, Wadih, et al. 435/5; 435/6 C12Q001/70 C12Q001/68.
-
- ☐ 3. [20040031067](#). 22 Aug 03. 12 Feb 04. Regulation of human skin healing. Herlyn, Meenhard, et al. 800/9; 435/455 435/6 C12N005/08 A01K067/00 C12N015/63 C12N015/87 C12Q001/68.
-
- ☐ 4. [20030229042](#). 20 Mar 03. 11 Dec 03. Methods and compositions for therapies using genes encoding secreted proteins. Barsoum, James G., et al. 514/44; 424/85.4 424/93.2 A61K048/00 A61K038/21.
-
- ☐ 5. [20030203488](#). 19 Mar 01. 30 Oct 03. Viral vectors and line for gene therapy. Mehtali, Majid, et al. 435/456; 435/235.1 C12N015/86 C12N007/00.
-
- ☐ 6. [20030192066](#). 28 May 02. 09 Oct 03. Minimal adenoviral vector. Zhang, Wei-Wei, et al. 800/8; 424/93.2 435/235.1 435/320.1 435/456 536/23.2 800/21 A01K067/00 C07H021/04 A61K048/00 C12N015/861 C12N007/00.
-
- ☐ 7. [20030165462](#). 05 Oct 01. 04 Sep 03. Deleted adenovirus vectors and methods of making and administering the same. Amalfitano, Andrea, et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N015/861 C12N007/00.
-
- ☐ 8. [20030157688](#). 14 Jan 00. 21 Aug 03. Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use. Von Seggern, Daniel J., et al. 435/235.1; 424/93.2 435/325 435/456 536/23.2 A61K048/00 C07H021/04 C12N007/00 C12N015/861.
-
- ☐ 9. [20030147854](#). 03 Jun 02. 07 Aug 03. Adenovirus vectors for gene therapy. Gregory, Richard J., et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 10. [20030103943](#). 14 Jan 03. 05 Jun 03. Multiple site delivery of adenoviral vector for the induction of angiogenesis. Rosengart, Todd K., et al. 424/93.2; 514/44 A61K048/00.
-
- ☐ 11. [20030040100](#). 23 Jul 01. 27 Feb 03. Cell for the propagation of adenoviral vectors. Brough, Douglas E., et al. 435/235.1; 435/239 435/325 536/23.72 536/24.1 C12N007/02 C12N005/02 C07H021/04 C12N005/00 C12N007/01 C12N007/00.
-
- ☐ 12. [20030026783](#). 03 Aug 01. 06 Feb 03. Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins. Abina, Amine. 424/93.2; 424/131.1 424/450 514/44 A61K048/00 A61K039/395 A61K009/127.
-
- ☐ 13. [20020193328](#). 13 Jul 01. 19 Dec 02. Use of gene product of adenovirus early region 4 ORF-6

to inhibit repair of double-strand breaks in DNA. Ketner, Gary. 514/44; 424/93.2 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.

☐ 14. 20020168342. 13 Nov 01. 14 Nov 02. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods. Wang, Qing, et al. 424/93.2; 424/199.1 435/456 A61K048/00 A61K039/12 C12N015/861.

☐ 15. 20020164782. 11 May 00. 07 Nov 02. Adenovirus vectors for gene therapy. Gregory, Richard J., et al. 435/320.1; 424/93.2 435/325 A61K048/00 C12N015/74 C12N005/06.

☐ 16. 20020106382. 13 Jul 01. 08 Aug 02. Modified adenovirus and uses thereof. Young, Charles S.H., et al. 424/233.1; 424/199.1 424/93.2 435/5 435/91.33 C12Q001/70 C12P019/34 A61K048/00 A01N063/00 A61K039/12 A61K039/23 A61K039/235.

☐ 17. 20020102731. 12 Feb 01. 01 Aug 02. Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof. Hearing, Patrick, et al. 435/456; 435/320.1 C12N015/861.

☐ 18. 20020098571. 08 Mar 00. 25 Jul 02. Rapid generation of recombinant adenoviral vectors. Davidson, Beverly L., et al. 435/235.1; C12N007/00 C12N007/01.

☐ 19. 20020088014. 10 Oct 01. 04 Jul 02. Minimal adenovirus mediated recombinant vaccine. Fang, Xiangming, et al. 800/8; 435/235.1 435/320.1 435/456 A01K067/00 C12N015/867 C12N015/861 C12N007/00 C12N007/01.

☐ 20. 20020051966. 30 Apr 01. 02 May 02. Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease. Massie, Bernard, et al. 435/5; 435/235.1 435/236 435/320.1 435/456 435/7.1 536/23.1 C12N007/00 C12Q001/70 G01N033/53 C12N015/861 C12N007/04 C12N015/09 C12N015/70 C07H021/02 C07H021/04 C12N015/74.

☐ 21. 20020028194. 08 Aug 01. 07 Mar 02. Transgene expression systems. Kaplan, Johanne, et al. 424/93.21; 435/320.1 435/456 A61K048/00 C12N015/861.

☐ 22. 20020025307. 20 Jun 01. 28 Feb 02. Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues. Koeneman, Kenneth S., et al. 424/93.21; 514/171 514/256 514/263.38 514/44 514/8 A61K048/00 A61K038/17 A61K031/56 A61K031/505 A61K031/522.

☐ 23. 20010046965. 08 Feb 01. 29 Nov 01. Adenovirus E1-complementing cell lines. Ayares, David, et al. 514/44; 435/235.1 435/325 435/456 A61K048/00 C12N007/01 C12N005/06 C12N015/861.

☐ 24. 20010041679. 19 Jul 99. 15 Nov 01. MULTIPLE SITE DELIVERY OF ADENOVIRAL VECTOR FOR THE INDUCTION OF ANGIOGENESIS. ROSENGART, TODD K, et al. 514/44; 424/93.1 A61K048/00.

☐ 25. 20010026794. 09 Feb 01. 04 Oct 01. Methods of preparing and using a viral vector library. Kovesdi, Imre, et al. 424/93.21; 435/235.1 435/5 A61K048/00 C12Q001/70 C12N007/01.

☐ 26. 6730507. 06 Apr 99; 04 May 04. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Graham; Frank L., et al. 435/235.1; 435/320.1 435/325 435/366 435/369. C12N005/10 C12N007/01 C12N015/861.

☐ 27. 6696423. 25 Feb 00; 24 Feb 04. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta. Barsoum; James G., et al. 514/44; 424/93.1 435/320.1 435/325 435/455 536/23.1. A61K048/00 C12N015/00 C12N015/63 C12N015/87 C02H021/04.

☐ 28. 6686200. 31 Aug 93; 03 Feb 04. Methods and compositions for the large scale production of recombinant adeno-associated virus. Dong; Jianyun, et al. 435/457; 435/235.1 435/320.1 435/325 435/366 435/455 435/456 435/69.1. C12N005/10 C12N015/861 C12N015/869 C12N015/63.

☐ 29. 6677135. 06 Nov 98; 13 Jan 04. Ret ligand (RetL) for stimulating neural and renal growth. Sanicola-Nadel; Michele, et al. 435/69.1; 435/325 514/44 514/455 530/300 530/350 536/18.7 536/22.1 536/23.1 536/23.5. C12P021/06 A61K038/00 C07K002/00 C07K004/00 C07K005/00.

☐ 30. 6664385. 23 Nov 98; 16 Dec 03. Kidney injury-related molecules. Sanicola-Nadel; Michele, et al. 536/23.4; 435/325 435/69.1 435/69.7 536/23.5. C07H021/04.

☐ 31. 6642052. 30 Apr 01; 04 Nov 03. Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease. Massie; Bernard, et al. 435/463; 435/235.1 435/236 435/320.1 435/6. C12N015/87 C12N015/861.

☐ 32. 6599744. 01 May 00; 29 Jul 03. Viral expression vectors comprising a ribosomal promoter sequence. Askari; Frederick K.. 435/455; 435/320.1 435/325 435/340 435/70.1 536/24.1. C12N015/00 C12N015/63 C12N005/00 C12N005/02 C12N015/85 C12N015/87 C07H021/04.

☐ 33. 6576463. 18 Jan 00; 10 Jun 03. Hybrid vectors for gene therapy. Kasahara; Noriyuki, et al. 435/320.1; 424/93.1 424/93.2 424/93.6 435/235.1 435/455 435/456 435/457 435/69.1. C12N015/86 C12N015/861 C12N015/867 C12N015/63 C12N015/64.

☐ 34. 6518255. 19 Jul 99; 11 Feb 03. Multiple site delivery of adenoviral vector directly into muscle for the induction of angiogenesis. Rosengart; Todd K., et al. 514/44; 424/93.1 424/93.2 435/455. A61K048/00 A61K035/00 C12N015/09.

☐ 35. 6485720. 08 Aug 01; 26 Nov 02. Transgene expression systems. Kaplan; Johanne, et al. 424/93.2; 424/93.1 424/93.6 435/320.1 435/325 435/366 435/455 435/456 435/457 435/69.1. A61K048/00 C12N015/861 C12N015/63 C12P021/00.

☐ 36. 6451596. 02 May 00; 17 Sep 02. Helper adenovirus vectors. Chamberlain; Jeffrey S., et al. 435/325; 435/235.1 435/320.1 435/456 536/23.1 536/24.1. C12N015/86 C12N015/861 C12N005/06 C12N007/01 C07H021/04.

☐ 37. 6387368. 11 Apr 00; 14 May 02. Hybrid adenovirus-AAV virus and methods of use thereof. Wilson; James M., et al. 424/93.2; 424/93.1 424/93.6 435/235.1 435/320.1 435/325 435/366 435/369 435/455 435/456 435/457 435/5 435/6 435/91.4 435/91.41 435/91.42. A61K048/00 C12N015/861 C12N015/864 C12N005/10 C12Q001/70.

☐ 38. 6358507. 12 Oct 99; 19 Mar 02. Transgene expression systems. Kaplan; Johanne, et al. 424/93.2; 424/93.6 435/320.1 435/325 435/366 435/371 435/455 435/456 435/69.1 435/91.1 435/91.4 435/91.41 435/91.42. A61K048/00 C12N015/63 C12N015/861 C12N015/34.

☐ 39. 6328958. 27 Aug 99; 11 Dec 01. Deleted adenovirus vectors and methods of making and administering the same. Amalfitano; Andrea, et al. 424/93.2; 435/320.1 435/455 435/91.4 514/44.

A61K048/00 C12N015/88.

-
- ☐ 40. 6251871. 13 Aug 97; 26 Jun 01. P16 expression constructs and their application in cancer therapy. Jin; Xiaomei, et al. 514/44; 435/320.1 536/23.5. A61K048/00 C12N015/86 C07H021/04.
-
- ☐ 41. 6251677. 08 Feb 99; 26 Jun 01. Hybrid adenovirus-AAV virus and methods of use thereof. Wilson; James M., et al. 435/457; 424/93.2 424/93.6 435/320.1 435/325 435/366 435/369 435/456 435/463 536/23.1 536/23.72. C12N015/861 C12N015/864 C12N005/10 C12N015/63 A61K048/00.
-
- ☐ 42. 6204060. 31 Mar 97; 20 Mar 01. Viral vectors and line for gene therapy. Mehtali; Majid, et al. 435/456; 435/320.1 435/325 435/366 435/369 435/370. C12N015/86 C12N005/10 C12N015/63.
-
- ☐ 43. 6203975. 21 Oct 99; 20 Mar 01. Adenovirus and method of use thereof. Wilson; James M., et al. 435/5; 435/320.1 435/325 435/455 435/456 435/457 435/6 435/91.4 435/91.41 435/91.42. C12Q001/68 C12Q001/70 C12N015/861 C12N015/64 C12N005/10.
-
- ☐ 44. 6171855. 28 May 98; 09 Jan 01. Vectors. Askari; Frederick K.. 435/320.1; 435/325 435/455 435/70.1 536/24.1. C07H021/04 C12N005/00 C12N015/63 C12P021/04.
-
- ☐ 45. 6100086. 14 Apr 97; 08 Aug 00. Transgene expression systems. Kaplan; Johanne, et al. 435/320.1; 435/457 435/458 536/23.72 552/544. C12N015/86 C07J009/00.
-
- ☐ 46. 6093567. 10 Feb 99; 25 Jul 00. Gene therapy for cystic fibrosis. Gregory; Richard J., et al. 435/320.1; 424/93.2. A61K048/00.
-
- ☐ 47. 6083750. 05 Feb 99; 04 Jul 00. Adenovirus vectors. Chamberlain; Jeffrey S., et al. 435/369; 435/320.1 435/325. C12N005/10 C12N015/86.
-
- ☐ 48. 6063622. 05 Feb 99; 16 May 00. Adenovirus vectors. Chamberlain; Jeffrey S., et al. 435/369; 435/235.1 435/320.1 435/325. C12N005/10 C12N007/01 C12N015/86.
-
- ☐ 49. 6057158. 18 May 99; 02 May 00. Adenovirus vectors. Chamberlain; Jeffrey S., et al. 435/456; 435/325 435/369. C12N005/10 C12N015/861.
-
- ☐ 50. 6028059. 24 Jun 96; 22 Feb 00. Methods for modulating protein function in cells using intracellular antibody homologues. Curiel; David T., et al. 514/44; A61K048/00.
-
- ☐ 51. 6020191. 14 Apr 97; 01 Feb 00. Adenoviral vectors capable of facilitating increased persistence of transgene expression. Scaria; Abraham, et al. 435/320.1; 536/23.5. C12N015/86.
-
- ☐ 52. 6001557. 25 Aug 97; 14 Dec 99. Adenovirus and methods of use thereof. Wilson; James M., et al. 435/5; 435/239 435/320.1 435/325 435/366 435/367 435/368 435/369 435/6 435/91.4 530/300. C12Q001/70 C12N015/86 C12N015/64.
-
- ☐ 53. 5994132. 23 Oct 96; 30 Nov 99. Adenovirus vectors. Chamberlain; Jeffrey S., et al. 435/369; 435/320.1. C12N005/08 C12N005/10 C12N015/86.
-
- ☐ 54. 5994106. 26 Nov 96; 30 Nov 99. Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus. Kovessdi; Imre, et al. 435/91.4; 435/320.1 435/325 435/366 435/456. C12N005/10 C12N015/64 C12N015/86.
-

-
- ☐ 55. 5985846. 07 Jun 95; 16 Nov 99. Gene therapy for muscular dystrophy. Kochanek; Stefan, et al. 514/44; 435/320.1. A01N043/04 C12N015/00.
-
- ☐ 56. 5981504. 09 Oct 97; 09 Nov 99. Genetic induction of receptors for targeted radiotherapy. Buchsbaum; Donald J., et al. 514/44; 424/1.41 424/1.45 424/1.49 424/1.69. A61K048/00.
-
- ☐ 57. 5981275. 14 Apr 97; 09 Nov 99. Transgene expression system for increased persistence. Armentano; Donna, et al. 435/320.1; C12N015/00.
-
- ☐ 58. 5981225. 16 Apr 98; 09 Nov 99. Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same. Kochanek; Stefan, et al. 435/69.1; 435/320.1 435/456 435/457 536/23.5 536/23.72 536/24.1. C12P021/00 C12N007/01 C12N015/12 C12N015/33.
-
- ☐ 59. 5902583. 11 Feb 97; 11 May 99. Genetic induction of receptors for targeted radiotherapy. Buchsbaum; Donald J., et al. 424/130.1; 424/1.17 424/1.41 424/1.49 424/1.65 514/44. A61K039/395 A61K051/00 A01N043/04.
-
- ☐ 60. 5891690. 26 Apr 96; 06 Apr 99. Adenovirus E1-complementing cell lines. Massie; Bernard. 435/456; 435/235.1 435/371. C12N005/10 C12N015/86 C12N015/87.
-
- ☐ 61. 5882877. 16 Jul 97; 16 Mar 99. Adenoviral vectors for gene therapy containing deletions in the adenoviral genome. Gregory; Richard J., et al. 435/320.1; 435/456 435/457. C12N015/00 C12N015/86.
-
- ☐ 62. 5871982. 25 Aug 97; 16 Feb 99. Hybrid adenovirus-AAV virus and methods of use thereof. Wilson; James M., et al. 435/457; 435/235.1 435/320.1 435/325. C12N015/10 C12N007/01 C12N005/10 C12N015/86.
-
- ☐ 63. 5869040. 07 Jun 95; 09 Feb 99. Gene therapy methods and compositions. Oin; Xiao-Oiang. 424/93.21; 435/320.1 435/366 435/69.1 536/23.5. A01N063/00.
-
- ☐ 64. 5856152. 28 Oct 94; 05 Jan 99. Hybrid adenovirus-AAV vector and methods of use therefor. Wilson; James M., et al. 435/457; 435/320.1 435/369. C12N015/10 C12N015/64 C12N015/86.
-
- ☐ 65. 5851806. 14 Dec 95; 22 Dec 98. Complementary adenoviral systems and cell lines. Kovesdi; Imre, et al. 435/91.41; 435/320.1 435/325 435/366 536/24.2. C12P019/34 C12N015/11 C12N005/16 C12N005/22.
-
- ☐ 66. 5670488. 13 Oct 93; 23 Sep 97. Adenovirus vector for gene therapy. Gregory; Richard J., et al. 514/44; 424/93.2 435/320.1. A61K048/00 C12N015/00.
-
- ☐ 67. 5585362. 07 Jun 93; 17 Dec 96. Adenovirus vectors for gene therapy. Wilson; James M., et al. 514/44; 435/320.1 435/456. A61K048/00 C12N005/16 C12N015/63.
-
- ☐ 68. 5552309. 30 Sep 94; 03 Sep 96. Use of polyols for improving the introduction of genetic material into cells. March; Keith L.. 435/456; 424/426 424/93.1 424/93.2 435/235.1 435/320.1 435/458 514/44. A01N063/00 C12N005/00 C12N015/00.
-
- ☐ 69. 5518913. 22 Apr 94; 21 May 96. High level recombinant protein production using conditional helper-free adenovirus vector. Massie; Bernard, et al. 435/235.1; 435/320.1. C12N007/01 C12N015/85.
-

[Generate Collection](#)[Print](#)

Terms	Documents
E1 near5 delet\$ and complement\$ near5 293 near (cell or cells) and titer\$ near10 (plaque\$ or pfu\$)	69

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,6,55,154,155,156,312,399,biotech,biosci

>>> 135 is unauthorized

Set	Items	Description
?	s	(inducer? or repressor?) and complement? (5n) cell
		Processing
		Processing
		Processing
	Processed 10 of 34 files ...	
		Processing
	Processed 20 of 34 files ...	
		Processing
	Completed processing all files	
	210391	INDUCER?
	130174	REPRESSOR?
	1537506	COMPLEMENT?
	16642674	CELL
	69823	COMPLEMENT?(5N)CELL
S1	958	(INDUCER? OR REPRESSOR?) AND COMPLEMENT? (5N) CELL
?	s s1 and	(viral or virus or adenovir?)
		Processing
	Processed 10 of 34 files ...	
	Completed processing all files	
	958	S1
	1774578	VIRAL
	3292313	VIRUS
	221401	ADENOVIR?
S2	156	S1 AND (VIRAL OR VIRUS OR ADENOVIR?)
?	s s2 and	(virus or viral or adenovir?) (5n) gene? (5n) inducib? (5n) promoter?
		Processing
		Processing
		Processing
		Processing
		Processing
		Processing
	Processed 10 of 34 files ...	
		Processing
	>>>File 144 processing for GENE? stopped at GENETYCZNEGO	
		Processing
	Processed 20 of 34 files ...	
		Processing
	Processed 30 of 34 files ...	
		Processing
	Completed processing all files	
	156	S2
	3292313	VIRUS
	1774578	VIRAL
	221401	ADENOVIR?
	24895515	GENE?
	385780	INDUCIB?
	1020539	PROMOTER?
	1518	((VIRUS OR VIRAL) OR ADENOVIR?) (5N)GENE?(5N)INDUCIB?(5N)PROMOTER?
S3	2	S2 AND (VIRUS OR VIRAL OR ADENOVIR?) (5N) GENE? (5N) INDUCIB? (5N) PROMOTER?
?	d s3/9/1-2	
	Display 3/9/1	(Item 1 from file: 5)
	DIALOG(R)File	5:Biosis Previews(R)
	(c) 2004 BIOSIS.	All rts. reserv.

0007316508 BIOSIS NO.: 199090100987
 NEGATIVE GROWTH REGULATION IN A GLIOBLASTOMA TUMOR CELL LINE THAT
 CONDITIONALLY EXPRESSES HUMAN WILD-TYPE P53
 AUTHOR: MERCER W E (Reprint); SHIELDS M T; AMIN M; SAUVE G J; APPELLA E;

ROMANO J W; ULLRICH S J
AUTHOR ADDRESS: DEP PATHOLOGY FELS RES INST, TEMPLE UNIVERSITY SCH MED,
PHILADELPHIA, PA 19140, USA**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United
States of America 87 (16): p6166-6170 1990
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: To investigate the effect that human wild-type p53 (wt-p53)
expression has on cell proliferation we constructed a recombinant

-more-

?

Display 3/9/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.
plasmid, pM47, in which wt-p53 cDNA is under transcriptional control of
the hormone-**inducible** mouse mammary tumor **virus**
promoter linked to the dominant biochemical selection marker
gene Eco gpt. The pM47 plasmid was introduced into T98G cells
derived from a human glioblastoma multiforme tumor, and a stable clonal
cell line, GM47.23, was derived that conditionally expressed wt-p53
following exposure to dexamethasone. We show that induction of wt-p53
expression in exponentially growing cells inhibits cell cycle progression
and that the inhibitory effect is reversible upon removal of the
inducer or infection with simian ***virus*** 40. Moreover, when
growth-arrested cells are stimulated to proliferate, induction of wt-p53
expression inhibits G0/G1 progression into S phase and the cells
accumulate with a DNA content equivalent to cells arrested in the G0/G1
phase of the cell cycle. Taken together, these studies suggest that
wt-p53 may play a negative role in growth regulation.

DESCRIPTORS: **CELL PROLIFERATION COMPLEMENTARY DNA**

-more-

?

Display 3/9/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.
DESCRIPTORS:
MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Cell Biology;
Genetics; Oncology--Human Medicine, Medical Sciences
BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,
Animalia
COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates;
Vertebrates
CONCEPT CODES:
02508 Cytology - Human
03508 Genetics - Human
10052 Biochemistry methods - Nucleic acids, purines and pyrimidines
10062 Biochemistry studies - Nucleic acids, purines and pyrimidines
10506 Biophysics - Molecular properties and macromolecules
24005 Neoplasms - Neoplastic cell lines
24006 Neoplasms - Biochemistry
32500 Tissue culture, apparatus, methods and media
BIOSYSTEMATIC CODES:

-more-

?

Display 3/9/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.
86215 Hominidae

- end of record -

?

Display 3/9/2 (Item 1 from file: 98)
DIALOG(R)File 98:General Sci Abs/Full-Text
(c) 2004 The HW Wilson Co. All rts. reserv.

03796048 H.W. WILSON RECORD NUMBER: BGS198046048 (THIS IS THE FULLTEXT)
How cells respond to interferons.
AUGMENTED TITLE: review
Stark, George R
Kerr, Ian M; Williams, Bryan R. G
Annual Review of Biochemistry (Annu Rev Biochem) v. 67 ('98) p. 227-64
SPECIAL FEATURES: bibl il ISSN: 0066-4154
LANGUAGE: English
COUNTRY OF PUBLICATION: United States
RECORD TYPE: Abstract; Fulltext RECORD STATUS: Corrected or revised
record
WORD COUNT: 17780

ABSTRACT: Interferons play key roles in mediating antiviral and antigrowth responses and in modulating immune response. The main signaling pathways are rapid and direct. They involve tyrosine phosphorylation and activation

-more-

?

Display 3/9/2 (Item 1 from file: 98)
DIALOG(R)File 98:General Sci Abs/Full-Text
(c) 2004 The HW Wilson Co. All rts. reserv.
of signal transducers and activators of transcription factors by Janus tyrosine kinases at the cell membrane, followed by release of signal transducers and activators of transcription and their migration to the nucleus, where they induce the expression of the many gene products that determine the responses. Ancillary pathways are also activated by the interferons, but their effects on cell physiology are less clear. The Janus kinases and signal transducers and activators of transcription, and many of the interferon-induced proteins, play important alternative roles in cells, raising interesting questions as to how the responses to the interferons intersect with more general aspects of cellular physiology and how the specificity of cytokine responses is maintained. With permission, from the Annual Review of Biochemistry Volume 67, 1998, by Annual Reviews Inc. (<http://www.annurev.org>).

TEXT:

KEY WORDS: JAKs, STATs, signaling, antiviral, antigrowth, immunity

-more-

?

Display 3/9/2 (Item 1 from file: 98)
DIALOG(R)File 98:General Sci Abs/Full-Text
(c) 2004 The HW Wilson Co. All rts. reserv.

INTRODUCTION

Type I (predominantly a and b) and type II(g) interferons (IFNs) signal through distinct but related pathways. Enormous progress has been made in recent years in understanding how cells respond to IFNs, especially in uncovering the pathways that mediate inducible gene expression. We now know that these pathways involve (a) specific type I and type II receptors, which bind to the Janus kinases (JAKs), and (b) the signal transducers and activators of transcription (STATs), which in turn propagate the signals. Moreover, JAKs and STATs, discovered through investigations of IFN signaling, also are involved in many different cytokine- and growth

factor-mediated pathways. We know of four mammalian JAKs and seven STATs. Several recent reviews describe signaling by IFNs in relation to other cytokines and growth factors (1-5) and more general aspects of JAK-STAT function and the family relationships (6-10).

After activation by JAKs through phosphorylation of a specific tyrosine residue, STATs form homo- or heterodimers through mutual

-more-

?

Display 3/9/2 (Item 1 from file: 98)
DIALOG(R)File 98:General Sci Abs/Full-Text
(c) 2004 The HW Wilson Co. All rts. reserv.
phosphotyrosine-Src homology region 2 (SH2) interactions. STAT dimers bind to gamma-activated sequence (GAS) elements, which drive the expression of nearby target genes. Different GAS elements prefer different STAT dimers, helping to establish specificity. Both STAT1-2 heterodimers and STAT1 homodimers bind to p48, a member of the interferon regulatory factor (IRF) family. The resulting trimers--called IFN-stimulated gene factor 3 (ISGF3) in the case of the STAT1-2 heterodimer--bind to IFN-stimulated regulatory elements (ISREs) that are distinct from the GAS elements. ISREs drive the expression of most IFN α /b-regulated genes and a few IFN γ -regulated genes. This review describes the signaling pathways used to turn the IFN responses on and off and the functions of the induced proteins in mediating the major cellular responses to IFN. Many of the proteins involved in both signaling and responses have important alternative functions, which are also reviewed.

SIGNALING PATHWAYS
INTERFERON g

-more-

?

Display 3/9/2 (Item 1 from file: 98)
DIALOG(R)File 98:General Sci Abs/Full-Text
(c) 2004 The HW Wilson Co. All rts. reserv.
The proximal events of IFN γ signaling require the obligatory participation of five distinct proteins: type I integral membrane proteins IFNGR1 and IFNGR2 (the subunits of the IFN γ receptor) and JAK1, JAK2, and STAT1 (2, 11). Recent work has revealed that this signaling pathway is necessary, though not always sufficient, for induction of most if not all IFN γ -dependent biological responses in vitro and in vivo. IFN γ receptors are expressed on nearly all cell types, with the possible exception of mature erythrocytes, and display strict species specificity in their ability to bind IFN γ (12). Functionally active IFN γ receptors consist of at least two species-matched polypeptide chains (Figure 1). IFNGR1 (previously the a chain or CD 119w), a 90-kDa polypeptide encoded by genes on human chromosome 6 and murine chromosome 10, plays important roles in mediating ligand binding, ligand trafficking through the cell, and signal transduction (11, 12). IFNGR2 (previously the b chain or accessory factor-1), a 62-kDa polypeptide encoded by a gene on human chromosome 21 and murine chromosome 16, plays only a minor role in ligand binding but is required for signaling (11, 13, 14).

-more-

?

Display 3/9/2 (Item 1 from file: 98)
DIALOG(R)File 98:General Sci Abs/Full-Text
(c) 2004 The HW Wilson Co. All rts. reserv.

Three sets of experiments have implicated JAKs and STATs in mediating IFN γ -dependent cellular responses. First, isolation and **complementation** of mutant human **cell** lines have revealed that

JAK1 and JAK2 become selectively activated in IFN γ -treated cells and are required for the ligand-dependent activation of IFN γ -inducible target genes (1). Second, through biochemical approaches, STAT1--a novel latent cytosolic transcription factor--was isolated and shown to undergo rapid tyrosine phosphorylation and activation in IFN γ -treated cells (1, 2). Third, structure-function analyses of the intracellular domains of the two IFN γ receptor subunits identified constitutive, specific binding sites for JAK1 and JAK2. Moreover, IFN γ induced the formation of a specific phosphotyrosine binding site on the receptor for STAT1, thereby providing the mechanism linking the activated receptor to its signal transduction apparatus (11).

Based on these and other observations, a relatively complete model of IFN γ signaling has been formulated (Figure 2). In unstimulated cells, the

-more-

? s (adenovir? or viral) (5n) inducib? (5n) promoter? and packaging (5n) cell?

Processing

Processing

Processing

Processing

Processing

Processing

Processed 10 of 34 files ...

Processing

Processing

Processing

Processed 20 of 34 files ...

Processing

Processed 30 of 34 files ...

Completed processing all files

221401 ADENOVIR?

1774578 VIRAL

385780 INDUCIB?

1020539 PROMOTER?

691 (ADENOVIR? OR VIRAL) (5N) INDUCIB? (5N) PROMOTER?

279026 PACKAGING

22321112 CELL?

11164 PACKAGING(5N)CELL?

S4 7 (ADENOVIR? OR VIRAL) (5N) INDUCIB? (5N) PROMOTER? AND
PACKAGING (5N) CELL?

? rd s4

...completed examining records

S5 7 RD S4 (unique items)

? d s5/3/1-7

Display 5/3/1 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

137028732 CA: 137(3)28732m JOURNAL

Feasibility of generating adeno-associated virus packaging cell lines
containing inducible adenovirus helper genes

AUTHOR(S): Qiao, Chunping; Li, Juan; Skold, Anna; Zhang, Xudong; Xiao,
Xiao

LOCATION: Department of Molecular Genetics and Biochemistry and Gene
Therapy Center, University of Pittsburgh School of Medicine, Pittsburgh, PA
, 15261, USA

JOURNAL: J. Virol. (Journal of Virology) DATE: 2002 VOLUME: 76

NUMBER: 4 PAGES: 1904-1913 CODEN: JOVIAM ISSN: 0022-538X LANGUAGE:

English PUBLISHER: American Society for Microbiology

- end of record -

?

Display 5/3/2 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

134348969 CA: 134(25)348969r PATENT
Packaging cell lines expressing adenoviral pTP/DNA polymerase genes for
replication deficient adenoviral vectors
INVENTOR(AUTHOR): Romanczuk, Helen
LOCATION: USA
ASSIGNEE: Genzyme Corporation
PATENT: PCT International ; WO 200134825 A1 DATE: 20010517
APPLICATION: WO 2000US30186 (20001101) *US PV164465 (19991110) *US
PV180116 (20000203) *US PV194946 (20000406)
PAGES: 19 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/861A;
C12N-005/10B DESIGNATED COUNTRIES: AU; CA; JP DESIGNATED REGIONAL: AT; BE
; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR

- end of record -

?

Display 5/3/3 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

134014919 CA: 134(2)14919d PATENT
Packaging cell lines for lentivirus vectors with viral genes under the
control of ecdysone-inducible promoters
INVENTOR(AUTHOR): Dougherty, Joseph P.; Adelson, Martin E.; Kaul, Malvika
; Pacchia, Annmarie L.; Ron, Yacov
LOCATION: USA
ASSIGNEE: University of Medicine and Dentistry of New Jersey
PATENT: PCT International ; WO 200071678 A1 DATE: 20001130
APPLICATION: WO 2000US14448 (20000525) *US PV135949 (19990525)
PAGES: 37 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-005/02A;
C12N-007/00B; C12N-007/01B; C12N-007/02B DESIGNATED COUNTRIES: AU; CA; JP;
US DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT
; LU; MC; NL; PT; SE

- end of record -

?

Display 5/3/4 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

122207001 CA: 122(17)207001j PATENT
Replication-defective adenovirus vectors capable of carrying very large
DNA inserts for use in gene therapy
INVENTOR(AUTHOR): Perricaudet, Michel; Vigne, Emmanuelle; Yeh, Patrice
LOCATION: Fr.
ASSIGNEE: Rhone-Poulenc Rorer S.A.
PATENT: PCT International ; WO 9502697 A1 DATE: 950126
APPLICATION: WO 94FR851 (940708) *FR 938596 (930713) *FR 944590 (940418)
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: French CLASS: C12N-015/86A;
C12N-015/34B; C12N-005/10B; C12N-007/04B; C07K-014/075B
DESIGNATED COUNTRIES: AU; BB; BG; BR; BY; CA; CN; CZ; FI; HU; JP; KP; KR;
KZ; LK; LV; MG; MN; MW; NO; NZ; PL; RO; RU; SD; SK; UA; US; UZ; VN
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;
NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

- end of record -

?

Display 5/3/5 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2004 Thomson Derwent & ISI. All rts. reserv.

0329589 DBR Accession No.: 2004-01881 PATENT
Novel isolated nucleic acid molecule useful for delivering heterologous
gene to human or any animal, or for producing gutless adenoviral vector
particle - involving vector-mediated gene transfer and expression in
host cell for use in gene therapy
AUTHOR: VON SEGGERN D J; NEMEROW G R; HALLENBECK P; STEVENSON S;
SKRIPCHENKO Y
PATENT ASSIGNEE: VON SEGGERN D J; NEMEROW G R; HALLENBECK P; STEVENSON S
; SKRIPCHENKO Y 2003
PATENT NUMBER: US 20030157688 PATENT DATE: 20030821 WPI ACCESSION NO.:
2003-843463 (200378)
PRIORITY APPLIC. NO.: US 423783 APPLIC. DATE: 20000626
NATIONAL APPLIC. NO.: US 482682 APPLIC. DATE: 20000114
LANGUAGE: English

- end of record -

?

Display 5/3/6 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2004 Thomson Derwent & ISI. All rts. reserv.

0295781 DBR Accession No.: 2002-17628 PATENT
Novel recombinant virus comprising hypoxia responsive element that controls
expression of genes which modulate the replication of viruses, useful
for treating cancer - recombinant vector expression in cell culture use
in disease therapy and gene therapy
AUTHOR: VAN MEIR E; NICHOLSON A C; POST D E
PATENT ASSIGNEE: UNIV EMORY 2002
PATENT NUMBER: WO 200226192 PATENT DATE: 20020404 WPI ACCESSION NO.:
2002-471244 (200250)
PRIORITY APPLIC. NO.: US 235283 APPLIC. DATE: 20000926
NATIONAL APPLIC. NO.: WO 2001US30236 APPLIC. DATE: 20010926
LANGUAGE: English

- end of record -

?

Display 5/3/7 (Item 3 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2004 Thomson Derwent & ISI. All rts. reserv.

0292113 DBR Accession No.: 2002-13960
Left ventricular targeting of reporter gene expression in vivo by human
BNPpromoter in an adenoviral vector - adeno virus vector-mediated gene
transfer, expression in heart cell and transgenic mouse for
cardiovascular disease gene therapy
AUTHOR: LAPOINTE MC; YANG XP; CARRETERO OA; HE Q
CORPORATE AFFILIATE: Henry Ford Hosp
CORPORATE SOURCE: LaPointe MC, Henry Ford Hosp, Hypertens and Vasc Res Div,
2799 W Grand Blvd, Detroit, MI 48202 USA
ISSN: 0363-6135 CODEN: 0363-6135; AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND
CIRCULATORY PHYSIOLOGY; (2002) 283, 4, H1439-H1445
LANGUAGE: English

- end of record -

?

? d s5/9/4
Display 5/9/4 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

122207001 CA: 122(17)207001j PATENT
Replication-defective adenovirus vectors capable of carrying very large
DNA inserts for use in gene therapy

INVENTOR(AUTHOR): Perricaudet, Michel; Vigne, Emmanuelle; Yeh, Patrice
LOCATION: Fr.
ASSIGNEE: Rhone-Poulenc Rorer S.A.
PATENT: PCT International ; WO 9502697 A1 DATE: 950126
APPLICATION: WO 94FR851 (940708) *FR 938596 (930713) *FR 944590 (940418)
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: French CLASS: C12N-015/86A;
C12N-015/34B; C12N-005/10B; C12N-007/04B; C07K-014/075B
DESIGNATED COUNTRIES: AU; BB; BG; BR; BY; CA; CN; CZ; FI; HU; JP; KP; KR;
KZ; LK; LV; MG; MN; MW; NO; NZ; PL; RO; RU; SD; SK; UA; US; UZ; VN
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;
NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG
SECTION:
CA203001 Biochemical Genetics

-more-

?

Display 5/9/4 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.
CA201XXX Pharmacology
IDENTIFIERS: adenovirus defective gene therapy vector
DESCRIPTORS:
Vaccines...
adenovirus gene therapy vectors for use in; replication-defective
adenovirus vectors capable of carrying very large DNA inserts for use
in gene therapy
Animal cell line...
for packaging of defective adenovirus vectors; replication-defective
adenovirus vectors capable of carrying very large DNA inserts for use
in gene therapy
Virus,animal, Epstein-Barr... Virus,animal, hepatitis B... Virus,animal,
human immunodeficiency... Virus,animal, human immunodeficiency 1...
Virus,animal, pseudorabies...
gene for antigens of, in gene therapy vectors; replication-defective
adenovirus vectors capable of carrying very large DNA inserts for use
in gene therapy

-more-

?

Display 5/9/4 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.
Animal growth regulators... Animal growth regulators,brain-derived
neurotrophic factors... Animal growth regulators,ciliary neurotrophic
factors... Antigens... Antigens,tumor... Blood-coagulation factors...
Enzymes... Enzymes,neurotransmitter-metabolizing... Hormones... Interferons
... Lipoproteins,apo-... Lipoproteins,apo-, A-I... Lipoproteins,apo-, A-IV
... Lipoproteins,apo-, E... Lymphokines and Cytokines... Lymphokines and
Cytokines,tumor necrosis factor... Proteins,specific or class, dystrophins
...
gene for, in gene therapy vectors; replication-defective adenovirus
vectors capable of carrying very large DNA inserts for use in gene
therapy
Genetic element,encapsidation signal...
in adenovirus vectors; replication-defective adenovirus vectors capable
of carrying very large DNA inserts for use in gene therapy
Gene,animal, anti-onco-...
in gene therapy vectors; replication-defective adenovirus vectors
capable of carrying very large DNA inserts for use in gene therapy

-more-

?

Display 5/9/4 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

Gene,microbial, E1... Gene,microbial, E2... Gene,microbial, E4...

Gene,microbial, L1... Gene,microbial, L2... Gene,microbial, L3...

Gene,microbial, L5...

inactivation of; replication-defective adenovirus vectors capable of
carrying very large DNA inserts for use in gene therapy

Genetic element...

inverted terminal repeat (ITR), in adenovirus vectors;

replication-defective adenovirus vectors capable of carrying very large
DNA inserts for use in gene therapy

Gene,microbial...

L4, inactivation of; replication-defective adenovirus vectors capable
of carrying very large DNA inserts for use in gene therapy

Genetic element,long terminal repeat...

mouse mammary tumor virus, in gene therapy vectors;

replication-defective adenovirus vectors capable of carrying very large
DNA inserts for use in gene therapy

Corticosteroids,gluco-,biological studies...

-more-

?

Display 5/9/4 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

promoter inducible by, in gene therapy vectors; replication-defective
adenovirus vectors capable of carrying very large DNA inserts for use
in gene therapy

Therapeutics,geno-... Virus,animal, adenovirus 2... Virus,animal,

adenovirus 5... Virus,animal, adeno-...

replication-defective adenovirus vectors capable of carrying very large
DNA inserts for use in gene therapy

CAS REGISTRY NUMBERS:

9001-25-6 9001-28-9 9061-61-4 61912-98-9 83869-56-1 106096-92-8

106096-93-9 113189-02-9 130939-66-1 148499-03-0 gene for, in gene
therapy vectors; replication-defective adenovirus vectors capable of
carrying very large DNA inserts for use in gene therapy

- end of record -

?

? e au=mehtali majid

Ref	Items	Index-term
E1	1	AU=MEHTALI M; +PAVIRANI A
E2	1	AU=MEHTALI M; ZACCHELLO F; ZANESCO L; SCARPA M
E3	87	*AU=MEHTALI MAJID
E4	60	AU=MEHTALI, M.
E5	63	AU=MEHTALI, MAJID
E6	1	AU=MEHTALIA D.
E7	5	AU=MEHTALIA S
E8	37	AU=MEHTALIA S D
E9	2	AU=MEHTALIA S.D.
E10	1	AU=MEHTALIA SD
E11	1	AU=MEHTALIA, S. D.
E12	1	AU=MEHTALIA, SHARAD D.

Enter P or PAGE for more

? e au=mehtali, majid

Ref	Items	Index-term
E1	87	AU=MEHTALI MAJID
E2	60	AU=MEHTALI, M.
E3	63	*AU=MEHTALI, MAJID

E4 1 AU=MEHTALIA D.
E5 5 AU=MEHTALIA S
E6 37 AU=MEHTALIA S D
E7 2 AU=MEHTALIA S.D.
E8 1 AU=MEHTALIA SD
E9 1 AU=MEHTALIA, S. D.
E10 1 AU=MEHTALIA, SHARAD D.
E11 1 AU=MEHTALIA, SURESH
E12 1 AU=MEHTALIA, SURESH D.

Enter P or PAGE for more
? s e1 and complement?
87 AU=MEHTALI MAJID
1537506 COMPLEMENT?
S6 23 AU='MEHTALI MAJID' AND COMPLEMENT?
? s s6 and adenovir?
23 S6
221401 ADENOVIR?
S7 14 S6 AND ADENOVIR?
? rd s7
...completed examining records
S8 6 RD S7 (unique items)
? d s8/3/1-6
Display 8/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0014109917 BIOSIS NO.: 200300068636

Complementing cell lines

AUTHOR: Vogels Ronald (Reprint); Havenga Menzo; **Mehtali Majid**
AUTHOR ADDRESS: Linschoren, Netherlands**Netherlands
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1265 (2): Dec. 10, 2002 2002
MEDIUM: e-file
PATENT NUMBER: US 6492169 PATENT DATE GRANTED: December 10, 2002 20021210
PATENT CLASSIFICATION: 435-325 PATENT ASSIGNEE: Crucell Holland, B.V.,
Leiden, Netherlands PATENT COUNTRY: USA
ISSN: 0098-1133 (ISSN print)
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?

Display 8/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0013081224 BIOSIS NO.: 200100253063

Defective **adenoviruses** and corresponding **complementation** lines

AUTHOR: Imler Jean-Luc (Reprint); **Mehtali Majid**; Pavirani Andrea
AUTHOR ADDRESS: Strasbourg, France**France
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1239 (3): Oct. 17, 2000 2000
MEDIUM: e-file
PATENT NUMBER: US 6133028 PATENT DATE GRANTED: October 17, 2000 20001017
PATENT CLASSIFICATION: 435-325 PATENT ASSIGNEE: Transgene S.A.,
Strasbourg, France PATENT COUNTRY: USA
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?

Display 8/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0012841071 BIOSIS NO.: 200100012910
Optimization of bovine coronavirus hemagglutinin-estrace glycoprotein
expression in E3 deleted bovine **adenovirus-3**
AUTHOR: Reddy P Seshidhar; Idamakanti Neeraja; Zakhartchouk Lexander N;
Babiuk Lorne A; **Mehtali Majid**; Tikoo Suresh K (Reprint
AUTHOR ADDRESS: Virology group, Veterinary Infectious Disease Organization,
University of Saskatchewan, Saskatoon, Saskatchewan, S7N 5E3, Canada**
Canada
JOURNAL: Virus Research 70 (1-2): p65-73 September, 2000 2000
MEDIUM: print
ISSN: 0168-1702
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?

Display 8/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0012308866 BIOSIS NO.: 200000027179
Porcine **adenovirus-3** as a helper-dependent expression vector
AUTHOR: Reddy P Seshidhar; Idamakanti Neeraja; Babiuk Lorne A; **Mehtali
Majid**; Tikoo Suresh K (Reprint
AUTHOR ADDRESS: Virology Group, Veterinary Infectious Disease Organization,
University of Saskatchewan, 120 Veterinary Road, Saskatoon, Saskatchewan,
S7N 5E3, Canada**Canada
JOURNAL: Journal of General Virology 80 (11): p2909-2916 Nov., 1999 1999
MEDIUM: print
ISSN: 0022-1317
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?

Display 8/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0012267734 BIOSIS NO.: 199900527394
Replication-defective bovine **adenovirus** type 3 as an expression
vector
AUTHOR: Reddy P Seshidhar; Idamakanti Neeraja; Chen Yan; Whale Tyler;
Babiuk Lorne A; **Mehtali Majid**; Tikoo Suresh Kumar (Reprint
AUTHOR ADDRESS: VIDO, University of Saskatchewan, 120 Veterinary Rd.,
Saskatoon, Saskatchewan, S7N 5E3, Canada**Canada
JOURNAL: Journal of Virology 73 (11): p9137-9144 Nov., 1999 1999
MEDIUM: print
ISSN: 0022-538X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?

Display 8/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0012172243 BIOSIS NO.: 199900431903
Transcription map and expression of bovine herpesvirus-1 glycoprotein D in
early region 4 of bovine **adenovirus-3**
AUTHOR: Baxi Mohit K; Babiuk Lorne A; **Mehtali Majid**; Tikoo Suresh K
(Reprint
AUTHOR ADDRESS: Virology Group, Veterinary Infectious Disease Organization,
University of Saskatchewan, Saskatoon, SK, S7N 5E3, Canada**Canada
JOURNAL: Virology 261 (1): p143-152 Aug. 15, 1999 1999
MEDIUM: print
ISSN: 0042-6822
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?
?